Ian Bridges

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +11

Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia

Frederick J. Raal, Robert C. Scott, Ransi Somaratne et al. · Circulation · 2012 · 500 citations

Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia

Raúl D. Santos, Andrea Ruzza, G. Kees Hovingh et al. · New England Journal of Medicine · 2020 · 180 citations · Full text

Effects of Evolocumab on Vitamin E and Steroid Hormone Levels

Dirk Blom, C. Stephen Djedjos, Maria Laura Monsalvo et al. · Circulation Research · 2015 · 83 citations · Full text

Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: A Double-Blind, Placebo-Controlled Trial

Lee S. Cohen, Cláudio N. Soares, Kimberly A. Yonkers et al. · Psychosomatic Medicine · 2004 · 72 citations